Illumina, Inc. $ILMN Shares Sold by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 4.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 299,361 shares of the life sciences company’s stock after selling 12,818 shares during the period. CIBC Private Wealth Group LLC owned about 0.20% of Illumina worth $28,430,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Assetmark Inc. increased its holdings in Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after purchasing an additional 96 shares during the period. Versant Capital Management Inc boosted its stake in shares of Illumina by 8.9% in the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after buying an additional 111 shares during the period. Archer Investment Corp boosted its stake in shares of Illumina by 12.9% in the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock valued at $102,000 after buying an additional 123 shares during the period. Callan Family Office LLC grew its position in shares of Illumina by 4.4% during the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after buying an additional 124 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in shares of Illumina by 4.7% during the third quarter. Parallel Advisors LLC now owns 2,834 shares of the life sciences company’s stock worth $269,000 after buying an additional 128 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ILMN. Wall Street Zen raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Piper Sandler lowered their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Barclays increased their price objective on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. TD Cowen restated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Finally, Stifel Nicolaus lifted their price objective on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $129.69.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $126.59 on Friday. The stock’s 50-day simple moving average is $131.25 and its 200-day simple moving average is $120.45. The firm has a market capitalization of $19.36 billion, a PE ratio of 23.23, a price-to-earnings-growth ratio of 2.35 and a beta of 1.45. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Expanded Labcorp collaboration to drive NGS adoption, expand distributed testing access, generate evidence for payer coverage and develop new oncology tests—provides a clear commercial growth pathway for Illumina’s oncology sequencing business. Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
• Positive Sentiment: Quarterly / sector commentary highlights Illumina as “firing on all cylinders,” reinforcing that recent earnings and revenue trends support upside in sequencing product and services demand. Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders
• Neutral Sentiment: Analyst fair-value modeling saw only a very small adjustment (from $135.94 to $136.05), signaling modest change to the baseline valuation despite active coverage shifts—mixed views persist across the Street. How The Illumina (ILMN) Story Is Shifting With 2026 Expectations And Mixed Street Views
• Neutral Sentiment: Broader analyst / comparative write-ups and stock-screen coverage (including independent company analyses) are circulating but don’t add a clear directional push—useful for longer-term thesis rather than immediate catalyst. Analyzing Illumina (NASDAQ:ILMN) and CervoMed (NASDAQ:CRVO)
• Negative Sentiment: Some strategists warn that recent share gains may already price in a stronger Q4 and 2026 outlook, which raises the risk of limited near-term upside or a pullback if execution or macro assumptions slip. ILMN Stock Gains Following Expanded Collaboration With Labcorp

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.